Six Bioactive Peptides from Loach Fish Show Antioxidant, Blood Pressure, and Cholesterol Activity | Research

The takeaway

Six peptides isolated from hydrolyzed loach fish protein demonstrated antioxidant activity, ACE inhibition (blood pressure lowering potential), and cholesterol esterase inhibition, with molecular docking revealing their enzyme-binding mechanisms.

Triple bioactivity
The six loach fish peptides showed three health-relevant activities in one package: antioxidant defense, blood pressure enzyme inhibition, and cholesterol absorption enzyme inhibition

What the researchers found

Six peptides were identified from hydrolyzed loach protein: D-1 (SERDPSNIKWGDAGAQ), D-2 (TVDGPSGKLWR), D-3 (NDHFVKL), D-4 (AFRVPTP), D-5 (DAGAGIAL), and D-6 (VSVVDLTVR). All showed antioxidant activity, with the <3 kDa fraction exhibiting the strongest DPPH, hydroxyl radical, and superoxide radical scavenging ability.

Peptide D-4 showed ACE inhibitory activity with an IC50 of 95.07 μg/mL (0.12 mM), and D-2 also inhibited ACE. For cholesterol reduction, D-2 inhibited pancreatic cholesterol esterase (IC50 3.19 mg/mL, 2.62 mM), with D-3 and D-6 also showing CE inhibitory activity. Molecular docking confirmed these peptides bind to key amino acids in the catalytic domains of both enzymes.

Why it matters

Food-derived bioactive peptides are an increasingly important area of functional food research. Finding peptides that simultaneously combat oxidative stress, potentially lower blood pressure (via ACE inhibition), and reduce cholesterol absorption from a common food fish provides a natural, food-based approach to cardiovascular health. These peptides could be developed into functional food ingredients or nutraceutical products.

How the study worked

Loach fish protein was hydrolyzed using alkaline protease, and the hydrolysate was separated by membrane filtration into fractions of different molecular weights. The <3 kDa fraction showing the highest antioxidant activity was further purified by gel filtration chromatography. Peptide sequences were identified using LC-MS/MS. Bioactivities were assessed through in vitro antioxidant assays (DPPH, hydroxyl radical, superoxide radical scavenging, reducing power), ACE inhibition assay, and pancreatic cholesterol esterase inhibition assay. Molecular docking was used to investigate binding mechanisms.

What this study cannot tell us

All bioactivity testing was performed in vitro (test tube), which does not guarantee these peptides would survive digestion, be absorbed, or remain active in the human body. The ACE and CE inhibition IC50 values, particularly for CE, are relatively high, suggesting modest potency. The molecular docking provides predicted binding mechanisms but not experimental proof. No animal or human studies were conducted. The peptide yields and practical feasibility of large-scale production were not assessed.

How to read the evidence

This is a basic in vitro study with no animal or human data. While the peptide identification and mechanism work are solid, the real-world health relevance of these peptides remains unproven. In vitro ACE and CE inhibition does not guarantee physiological effects.

When this study was published

Published in 2023, this study reflects the current boom in food-derived bioactive peptide discovery. The field is moving toward validating these in vitro findings with animal and human studies.

The bigger picture

The discovery of bioactive peptides from food proteins is a rapidly growing field at the intersection of food science and pharmacology. Fish-derived peptides are particularly promising because fish is already a health food in many cultures. These loach-derived peptides join a large catalog of food peptides from dairy (casein-derived ACE inhibitors), soy, and marine sources that show health benefits. The multi-functional nature of these peptides — antioxidant, ACE inhibition, and cholesterol reduction in one package — is particularly attractive for functional food development.

Questions still open

Would these peptides survive gastrointestinal digestion and be absorbed in amounts sufficient to produce measurable health effects?
Could the ACE-inhibiting peptide D-4 lower blood pressure in animal models at achievable dietary doses?
How do these loach-derived peptides compare in potency to established food-derived ACE inhibitors from dairy or other marine sources?

Common questions

Can eating fish actually lower blood pressure through these peptides?

Fish consumption is associated with cardiovascular benefits, and bioactive peptides may contribute to this effect. However, whether the specific peptides identified in this study survive digestion, are absorbed, and reach meaningful blood levels is unknown. The ACE inhibition shown in test tubes doesn't guarantee the same effect in the body. More research with animal models and eventually human studies would be needed to confirm any blood pressure-lowering benefit.

What is ACE and why does inhibiting it matter?

ACE (angiotensin-converting enzyme) is an enzyme that produces a hormone called angiotensin II, which constricts blood vessels and raises blood pressure. ACE inhibitor drugs (like lisinopril and enalapril) are among the most prescribed blood pressure medications. Food-derived peptides that inhibit ACE could offer a natural, dietary approach to blood pressure management, though they are much less potent than pharmaceutical ACE inhibitors.

Read the original research

Multiple Bioactivities of Peptides from Hydrolyzed Misgurnus anguillicaudatus.

Molecules (Basel, Switzerland), 28(6)

View on PubMed ↗Publisher’s paper ↗

Citation

Dou, Baojie; Wu, Xudong; Xia, Zihan; Wu, Guanghao; Guo, Quanyou; Lyu, Mingsheng; Wang, Shujun. (2023). Multiple Bioactivities of Peptides from Hydrolyzed Misgurnus anguillicaudatus.. Molecules (Basel, Switzerland), 28(6). https://doi.org/10.3390/molecules28062589